Brought to you by 
SARcode develops Sunesis' LFA-1 IP for inflammation
30 Jan 2023
Executive Summary
In order to concentrate more on oncology, Sunesis (uses its Tethering discovery engine to identify small molecules) has licensed biopharma SARcode exclusive worldwide rights to patents and know-how covering inhibitors of leukocyte integrin function-associated antigen-1 (LFA-1).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SARcode develops Sunesis' LFA-1 IP for inflammation
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice